A suite of activity-based probes for human cytochrome P450 enzymes

Journal of the American Chemical Society

Volumn 131, Issue 30, 2009, Pages 10692-10700

  Wright, Aaron T ^a   Song, Joongyu D ^a   Cravatt, Benjamin F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVITY-BASED; ACTIVITY-BASED PROBE; AROMATASE; ARYL ALKYNES; BREAST CANCER; CHEMICAL ARCHITECTURE; CLICK CHEMISTRY; CLINICAL USE; COOPERATIVITY EFFECTS; CYTOCHROME P450; ENDOGENOUS SIGNALING; HUMAN CYTOCHROME; IN-VITRO; MICROSOMAL P450S; MOUSE LIVER; NEW APPLICATIONS; OPTIMAL SETS; PROBE STRUCTURES; PROTEIN PROFILING; TERMINAL ALKYNE;

ACETYLENE; BIOCHEMISTRY; CATALYSTS; DRUG INTERACTIONS; ENZYMES; FUNCTIONAL GROUPS; LABELS; SYNTHESIS (CHEMICAL);

PROBES;

ALKYNE; ANASTROZOLE; AROMATASE INHIBITOR; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 ISOENZYME; DRUG METABOLIZING ENZYME; FORMESTANE; UNSPECIFIC MONOOXYGENASE; XENOBIOTIC AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME CHEMISTRY; ENZYME SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MOLECULAR PROBE; MOUSE; NONHUMAN; PROTEIN FAMILY;

ANDROSTENEDIONE; ANIMALS; AROMATASE INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; HUMANS; MICE; PHARMACEUTICAL PREPARATIONS; STAINING AND LABELING;

EID: 68049107457     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja9037609     Document Type: Article

References (64)

1. Guengerich, F. P.; Wu, Z.-L.; Bartleson, C. J. Biochem. Biophys. Res. Commun. 2005, 338, 465-69.
2. Denisov, I. L.; Makris, T. M.; Sligar, S. G.; Schlichting, I. Chem. Rev. 2005, 105, 2253-77.
3. Meunier, B.; de Visser, S. P.; Shaik, S. Chem. Rev. 2004, 104, 3947-3980.
4. Lamb, D. C.; Waterman, M. R.; Kelly, S. L.; Guengerich, F. P. Curr. Opin. Biotechnol. 2007, 18, 504-12.
5. Negishi, M.; Uno, T.; Darden, T. A.; Sueyoshi, T.; Pedersen, L. G. FASEB J. 1996, 10, 683-9.
6. Johnson, W. W. Curr. Drug Metab. 2008, 9, 344-51.
7. Guengerich, F. P. Chem. Res. Toxicol. 2008, 21, 70-83.
8. Ioannides, C.; Lewis, D. F. Curr. Top. Med. Chem. 2004, 4, 1767-88.
9. Bruno, R. D.; Njar, V. C. O. Bioorg. Med. Chem. 2007, 15, 5047-60.
10. Agúndez, J. A. G. Curr. Drug Metab. 2004, 5, 211-24.
11. McFadyen, M. C. E.; Melvin, W. T.; Murray, G. I. Mol. Cancer Ther. 2004, 3, 363-71.
12. Modungo, F.; Knoll, C.; Kanbour-Shakir, A.; Romkes, M. Breast Cancer Res. Treat. 2003, 82, 191-7.
13. Patterson, L. H.; Murray, G. I. Curr. Pharm. Des. 2002, 8, 1335-47.
14. McFadyen, M. C. E.; Cruickshank, M. E.; Miller, I. D.; McLeod, H. L.; Melvin, W. T.; Haites, N. E.; Parkin, D.; Murray, G. I. Br. J. Cancer 2001, 85, 242-6.
15. Rochat, B.; Morsman, J. M.; Murray, G. I.; Figg, W. D.; McLeod, H. L. J. Pharmacol. Exp. Ther. 2001, 296, 537-41.
16. Brueggemeier, R. W.; Hackett, J. C.; Diaz-Cruz, E. S. Endocr. Rev. 2005, 26, 331-45.
17. Yue, W.; Santen, R. J.; Wang, J.-P.; Hamilton, C. J.; Demers, L. M. Endocr. Relat. Cancer 1999, 6, 157-64.
18. Stark, K.; Guengerich, F. P. Drug Metab. Rev. 2007, 39, 627-37.
19. Wright, A. T.; Cravatt, B. F. Chem. Biol. 2007, 14, 1043-51.
20. Speers, A. E.; Cravatt, B. F. Chem. Biol. 2004, 11, 535-46.
21. Cravatt, B. F.; Wright, A. T.; Kozarich, J. W. Annu. Rev. Biochem. 2008, 77, 383-414.
22. Evans, M. J.; Cravatt, B. F. Chem. Rev. 2006, 106, 3279-3301.
23. Jessani, N.; Cravatt, B. F. Curr. Opin. Chem. Biol. 2004, 8, 54-59.
24. Kent, U. M.; Jushchyshyn, M. I.; Hollenberg, P. F. Curr. Drug Metab. 2001, 2, 215-43.
25. Foroozesh, M.; Primrose, G.; Guo, Z.; Bell, L. C.; Alworth, W. L.; Guengerich, F. P. Chem. Res. Toxicol. 1997, 10, 91-102.
26. Hollenberg, P. F.; Kent, U. M.; Bumpus, N. N. Chem. Res. Toxicol. 2008, 21, 189-205.
27. Roberts, E. S.; Hopkins, N. E.; Foroozeh, M.; Alworth, W. L.; Halpert, J. R.; Hollenberg, P. F. Drug Metab. Dispos. 1997, 10, 91-102.
28. Ortiz de Montellano, P. R.; Mico, B. A. J. Biol. Chem. 1985, 260, 3330-6.
29. Speers, A. E.; Adam, G. C.; Cravatt, B. F. J. Am. Chem. Soc. 2003, 125, 4686-7.
30. Takahashi, S.; Kuroyama, Y.; Sonogashira, K.; Hagihara, N. Synthesis 1980, 8, 627-29.
31. Yashima, E.; Matsushima, T.; Okamoto, Y. J. Am. Chem. Soc. 1997, 119, 6345-59.
32. Masahiko, S.; Yamada, S.-I.; Kuroda, T.; Imashiro, R.; Shimizu, T. Synthesis 2000, 12, 1677-80.
33. Stará, I. G.; Starý, I.; Kollárovič, A.; Teplý, F.; Šaman, D.; Fiedler, P. Tetrahedron 1998, 54, 11209-34.
34. Simoni, D.; Giannini, G.; Roberti, M.; Rondanin, R.; Baruchello, R.; Rossi, M.; Grisolia, G.; Invidiata, F. P.; Aiello, S.; Marino, S.; Cavallini, S.; Siniscalchi, A.; et al. J. Med. Chem. 2005, 48, 4293-99.
35. Fletcher, D. I.; Ganellin, C. R.; Piergentili, A.; Dunn, P. M.; Jenkinson, D. H. Bioorg. Med. Chem. 2007, 15, 5457-79.
36. Ortiz de Montellano, P. R.; Reich, N. O. J. Biol. Chem. 1984, 259, 4136-41.
37. Covey, D. F.; Hood, W. F.; Parikh, V. D. J. Biol. Chem. 1981, 256, 1076-79.
38. Metcalf, B. W.; Wright, C. L.; Burkhart, J. P.; Johnston, J. O. J. Am. Chem. Soc. 1981, 103, 3221-2.
39. Jones, E. R. H.; Jones, J. B.; Skattebøl, L.; Whiting, M. C. J. Chem. Soc. 1960, 3489-93.
40. Regal, K. A.; Schrag, M. L.; Kent, U. M.; Wienkers, L. C.; Hollenberg, P. F. Chem. Res. Toxicol. 2000, 13, 262-70.
41. Guengerich, F. P. Mol. Pharmacol. 1988, 33, 500-08.
42. Kent, U. M.; Mills, D. E.; Rajnarayanan, R. V.; Alworth, W. L.; Hollenberg, P. F. J. Pharmacol. Exp. Ther. 2002, 300, 549-58.
43. Lin, H.-L.; Kent, U. M.; Hollenberg, P. F. J. Pharmacol. Exp. Ther. 2002, 301, 160-7.
44. Koenigs, L. L.; Peter, R. M.; Thompson, S. J.; Rettie, A. E.; Trager, W. F. Drug Metab. Dispos. 1997, 25, 1407-15.
45. Koenigs, L. L.; Trager, W. F. Biochemistry 1998, 37, 13184-93.
46. von Weymarn, L. B.; Zhang, Q.-Y.; Ding, X.; Hollenberg, P. F. Carcinogenesis 2005, 26, 621-9.
47. Sharma, Y. N.; Zaman, A.; Kidwai, A. R. Tetrahedron 1964, 20, 87-90.
48. Kim, K.-H.; Fan, X.-J.; Nielsen, P. E. Bioconjugate Chem. 2007, 18, 567-72.
49. Guengerich, F. P. Chem. Biol. Interact. 1997, 106, 161-82.
50. Nelson, D. R.; Zeldin, D. C.; Hoffman, S. M. G.; Maltais, L. J.; Wain, H. M.; Nebert, D. W. Pharmacogenetics 2004, 14, 1-18.
51. Williams, J. A.; Hyland, R.; Jones, B. C.; Smith, D. A.; Hurst, S.; Goosen, T. C.; Peterkin, V.; Koup, J. R.; Ball, S. E. Drug Metab. Dispos. 2004, 32, 1201-8.
52. Wienkers, L. C.; Heath, T. G. Nat. Rev. Drug Discovery 2005, 4, 825-833.
53. Mwenifumbo, J. C.; Tyndale, R. F. Pharmacogenomics 2007, 8, 1385-402.
54. McFadyen, M. C.; Murray, G. I. Future Oncol. 2005, 1, 259-263.
55. Smith, D. A.; Jones, B. C. Biochem. Pharmacol. 1992, 44, 2089-98.
56. Kapelyukh, Y.; Paine, M. J.; Marechal, J. D.; Sutcliffe, M. J.; Wolf, C. R.; Roberts, G. Drug Metab. Dispos. 2008, 36, 2136-44.
57. Blobaum, A. L.; Kent, U. M.; Alworth, W. L.; Hollenberg, P. F. Chem. Res. Toxicol. 2002, 15, 1561-71.
58. Kharasch, E. D.; Hankins, D. C.; Jubert, C.; Thummel, K. E.; Taraday, J. K. Drug Metab. Dispos. 1999, 27, 717-23.
59. Fornander, T.; Hellstrom, A. C.; Moberger, B. J. Natl. Cancer Inst. 1993, 85, 1850-5.
60. Miller, W. R. Semin. Oncol. 2003, 30, 3-11.
61. Njar, V. C. O.; Grun, G.; Hartmann, R. W. J. Enzyme Inhib. Med. Chem. 1995, 9, 195-202.
62. Grimm, S. W.; Dyroff, M. C. Drug Metab. Dispos. 1997, 25, 598-602.
63. Tracy, T. S. Curr. Drug Metab. 2003, 4, 341-6.
64. Sohl, C. D.; Isin, E. M.; Eoff, R. L.; Marsch, G. A.; Stec, D. F.; Guengerich, F. P. J. Biol. Chem. 2008, 283, 7293-7308.